4th Drug Discovery Nexus

A new approach to drug discovery and preclinical areas is to understand how the diseases and infections are controlled at the molecular and physiological level and to target specific entities based on this knowledge.

Event Schedule
Event Speakers
Day 1 : Networking - Pitches
08:45 - 09:00 Chair Person Welcome
Welcome ceremony and speech
09:00 - 09:30 Keynote 1
09:30 - 10:00 Keynote 2
10:00 - 10:30 Keynote 3
10:30 - 12:10 Networking & Coffee
12:10 - 12:40 Keynote 4
12:10 - 12:40 Keynote 5
13:10 - 13:40 Keynote 6
14:00 - 14:30 Keynote 7
Day 2 : Networking - Pitches
  • Senior Principal Scientist, Chemistry, Merck
  • Founder, Director and Chief Scientist, Acumen Pharmaceuticals
  • COO, Cloud Pharmaceuticals
    Biomarkers for ascendancy drug discovery
  • Chief Scientific Officer, EssexBio
  • Quorum Innovations, Co-founder & CEO
  • Senior Director Moleculer Virology, Oncorus
    Focus on different gene therapy products including plasmid DNA, Viral vectors, Bacterial vectors, human gene editing technology & protein derived cellular gene therapy
  • Scientist II, Investigative Toxicology, Drug Safety Research and Evaluation, Takeda Pharmaceuticals
    Advanced Kidney and Liver Platforms for Drug Discovery
  • Head of Emerging Technologies, Novartis
  • Associate Scientific director, EMD Sereno, Inc
    Challenges in Phenotypic and Target based screening approaches
  • Vice President and Head of Discovery, Nektar Therapeutics
  • Vice President, R&D and Science Strategy, BERG Health
    Using model based strategies for better in vitro to in vivo translation. Drug development using QSP modeling. ADMET prediction models. DMPK for new drug modalities and combination therapies
  • voyager therapeutics
    Principal Scientist: Antibody/Protein Engineering
  • Vice President, AbbVie
    RNA optimisation a powerful tool for drug discovery
  • Principal Scientist, Kadmon LLC
    AI methods for in silico drug development
Event expired, so you can buy ticket at the moment.